Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03107026 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 491
- Enrollment target
NCT03107026 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 491 participants.
The verdict
NCT03107026, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 491 participants
- Enrollment target
Study Summary
A study to evaluate a drug (dasotraline) on the safety, effectiveness and how well the body tolerates it, in adults with moderate to severe binge eating disorder
Interventions
- DRUG Placebo
- DRUG dasotraline 4mg
- DRUG dasotraline 6mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 491 participants |
| Start Date | 2017-03-31 |
| Est. Completion | 2018-05-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03107026
The ClinicalTrials.gov registry entry for NCT03107026 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 491 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03107026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03107026 about?
NCT03107026 is a clinical study titled "A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder". A study to evaluate a drug (dasotraline) on the safety, effectiveness and how well the body tolerates it, in adults with moderate to severe binge eating disorder
What is the current status of trial NCT03107026?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 491 participants. The study started on 2017-03-31. Estimated completion is 2018-05-16.
What interventions are being tested in trial NCT03107026?
The interventions under investigation include: Placebo (DRUG), dasotraline 4mg (DRUG), dasotraline 6mg (DRUG).
Who is sponsoring clinical trial NCT03107026?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.